In conclusion, using integrated bioinformatics analysis, such as WGCNA and scRNA-seq, we identified hub genes (S100A8 and S100A9) as potential disease markers or therapeutic targets, which were not previously known to be associated with immune infiltration and CAVD. This evidence concerns the gene S100A9 and congenital bilateral aplasia of vas deferens from CFTR mutation.